174 related articles for article (PubMed ID: 28953011)
1. Self-limiting Ibrutinib-Induced Neutrophilic Panniculitis.
Stewart J; Bayers S; Vandergriff T
Am J Dermatopathol; 2018 Feb; 40(2):e28-e29. PubMed ID: 28953011
[TBL] [Abstract][Full Text] [Related]
2. Ibrutinib-Induced Neutrophilic Dermatosis.
El Halabi L; Cherif-Rebai K; Michot JM; Ghez D
Am J Dermatopathol; 2018 Mar; 40(3):198-200. PubMed ID: 29473834
[TBL] [Abstract][Full Text] [Related]
3. Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia.
Bitar C; Farooqui MZ; Valdez J; Saba NS; Soto S; Bray A; Marti G; Wiestner A; Cowen EW
JAMA Dermatol; 2016 Jun; 152(6):698-701. PubMed ID: 26982511
[TBL] [Abstract][Full Text] [Related]
4. Panniculitis in Patients Undergoing Treatment With the Bruton Tyrosine Kinase Inhibitor Ibrutinib for Lymphoid Leukemias.
Fabbro SK; Smith SM; Dubovsky JA; Gru AA; Jones JA
JAMA Oncol; 2015 Aug; 1(5):684-6. PubMed ID: 26182170
[No Abstract] [Full Text] [Related]
5. Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature.
Titus-Rains KS; Brown JN; Hammond JM
J Oncol Pharm Pract; 2018 Oct; 24(7):544-549. PubMed ID: 28714377
[TBL] [Abstract][Full Text] [Related]
6. Severe arthritic syndrome due to ibrutinib use for chronic lymphocytic leukemia.
Dasanu CA
J Oncol Pharm Pract; 2019 Jun; 25(4):1003-1005. PubMed ID: 29720040
[TBL] [Abstract][Full Text] [Related]
7. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
Barr PM; Robak T; Owen C; Tedeschi A; Bairey O; Bartlett NL; Burger JA; Hillmen P; Coutre S; Devereux S; Grosicki S; McCarthy H; Li J; Simpson D; Offner F; Moreno C; Zhou C; Styles L; James D; Kipps TJ; Ghia P
Haematologica; 2018 Sep; 103(9):1502-1510. PubMed ID: 29880603
[TBL] [Abstract][Full Text] [Related]
8. Cerebral aspergillosis in a patient on ibrutinib therapy-A predisposition not to overlook.
Faisal MS; Shaikh H; Khattab A; Albrethsen M; Fazal S
J Oncol Pharm Pract; 2019 Sep; 25(6):1486-1490. PubMed ID: 30045683
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.
O'Brien SM; Jaglowski S; Byrd JC; Bannerji R; Blum KA; Fox CP; Furman RR; Hillmen P; Kipps TJ; Montillo M; Sharman J; Suzuki S; James DF; Chu AD; Coutre SE
JAMA Oncol; 2018 May; 4(5):712-716. PubMed ID: 29470582
[TBL] [Abstract][Full Text] [Related]
10. Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre.
Uminski K; Brown K; Bucher O; Hibbert I; Dhaliwal DH; Johnston JB; Geirnaert M; Dawe DE; Banerji V
Curr Oncol; 2019 Oct; 26(5):e610-e617. PubMed ID: 31708654
[TBL] [Abstract][Full Text] [Related]
11. Vemurafenib-associated neutrophilic panniculitis: An emergent adverse effect of variable severity.
Maldonado-Seral C; Berros-Fombella JP; Vivanco-Allende B; Coto-Segura P; Vazquez-Lopez F; Perez-Oliva N
Dermatol Online J; 2013 Apr; 19(4):16. PubMed ID: 24021375
[TBL] [Abstract][Full Text] [Related]
12. Ibrutinib Use Complicated by Progressive Multifocal Leukoencephalopathy.
Hsiehchen D; Arasaratnam R; Raj K; Froehlich T; Anderson L
Oncology; 2018; 95(5):319-322. PubMed ID: 30045034
[TBL] [Abstract][Full Text] [Related]
13. [Recurrent neutrophilic panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib mesilate and dasatinib].
de Masson A; Bouvresse S; Clérici T; Mahé E; Saïag P
Ann Dermatol Venereol; 2011 Feb; 138(2):135-9. PubMed ID: 21333826
[TBL] [Abstract][Full Text] [Related]
14. Anterior chamber fibrinoid syndrome after cataract extraction in a patient on ibrutinib for B-cell chronic lymphocytic leukemia: a case report and review of the literature.
Kolomeyer AM; Hwang CK; Kim BJ
J Med Case Rep; 2018 Nov; 12(1):349. PubMed ID: 30442199
[TBL] [Abstract][Full Text] [Related]
15. Ibrutinib-induced polyneuropathy: A case report.
Cömert P; Albayrak M; Yıldız A; Şahin O; Öztürk HB; Reis Aras M
J Oncol Pharm Pract; 2020 Sep; 26(6):1501-1504. PubMed ID: 32028841
[TBL] [Abstract][Full Text] [Related]
16. Campylobacter infection in 4 patients treated with ibrutinib.
Sorin B; Vigneron J; Fadlallah J; Mondesir J; Fieschi C; Oksenhendler E; Galicier L; Malphettes M
Eur J Clin Microbiol Infect Dis; 2022 May; 41(5):849-852. PubMed ID: 35304678
[TBL] [Abstract][Full Text] [Related]
17. Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Coutré SE; Furman RR; Flinn IW; Burger JA; Blum K; Sharman J; Jones J; Wierda W; Zhao W; Heerema NA; Johnson AJ; Tran A; Zhou C; Bilotti E; James DF; Byrd JC; O'Brien S
Clin Cancer Res; 2017 Mar; 23(5):1149-1155. PubMed ID: 28073846
[No Abstract] [Full Text] [Related]
18. Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia.
Bennett CL; Berger JR; Sartor O; Carson KR; Hrushesky WJ; Georgantopoulos P; Raisch DW; Norris LB; Armitage JO
Br J Haematol; 2018 Jan; 180(2):301-304. PubMed ID: 27649938
[No Abstract] [Full Text] [Related]
19. Bilateral cystoid macular edema in a patient with chronic lymphocytic leukemia treated with ibrutinib.
Saenz-de-Viteri M; Cudrnak T
Leuk Lymphoma; 2019 Mar; 60(3):842-844. PubMed ID: 30188238
[No Abstract] [Full Text] [Related]
20. Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in the General Community: A Single-center Experience.
Ali N; Malik F; Jafri SIM; Naglak M; Sundermeyer M; Pickens PV
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S53-S61. PubMed ID: 28760303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]